Progress in platinum-derived drug development

Drugs of the Future

Volumn 37, Issue 11, 2012, Pages 795-806

  Farrell, Nicolas P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cancer therapy; Combinations; Cytotoxic drugs; Formulations; Platinum compounds

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; IFOSFAMIDE; LOBAPLATIN; NEDAPLATIN; OXALIPLATIN; PHENANTHRIPLATIN; PICOPLATIN; SATRAPLATIN; SPERMIDINE; TRIPLATIN TETRANITRATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; DNA BINDING; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG METABOLISM; DRUG STRUCTURE; GEOMETRY; HUMAN; IN VITRO STUDY; LONG TERM CARE; LUNG CARCINOMA; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PHOTOACTIVATION; REVIEW; STRUCTURE ACTIVITY RELATION; TESTIS CANCER;

EID: 84952987010     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2012.037.011.1830167     Document Type: Review

References (61)

1. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8): 573-84. (Pubitemid 47106628)
2. Hartmann, J.T., Lipp, H.P. Toxicity of platinum compounds. Expert Opin Pharmacother 2003, 4(6): 889-901. (Pubitemid 36722480)
3. Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 1998, 34(10): 1522-34. (Pubitemid 28446332)
4. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52(12): 1855-65. (Pubitemid 26419675)
5. Shen, D.-W., Pouliot, L.M., Hall, M.D., Gottesman, M.M. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012, 64(3): 706-21.
6. Stewart, D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63(1): 12-31. (Pubitemid 46810280)
7. DiMasi, J.A., Feldman, L., Seckler, A., Wilson, A. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 2010, 87(3): 272-7.
8. Farrell, N.P. Platinum formulations as anticancer drugs clinical and preclinical studies. Curr Top Med Chem 2011, 11(21): 2623-31.
9. Haxton, K.J., Burt, H.M. Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 2009, 98(7): 2299-316.
10. Jiang, W., Kim, B.Y., Rutka, J.T., Chan, W.C. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 2007, 4(6): 621-33. (Pubitemid 350199200)
11. Gabano, E., Ravera, M., Osella, D. The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view. Curr Med Chem 2009, 16(34): 4544-80.
12. Nowotnik, D.P., Cvitkovic, E. ProLindac (AP5346): A review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 2009, 61(13): 1214-9.
13. Duncan, R., Vicent, M.J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 2010, 62(2): 272-82.
14. Choy, H., Park, C., Yao, M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008, 14(6): 1633-8. (Pubitemid 351469447)
15. Sternberg, C.N., Petrylak, D.P., Sartor, O. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009, 27(32): 5431-8.
16. Bates, S.E., Amiri-Kordestani, L., Giaccone, G. Drug development: Portals of discovery. Clin Cancer Res 2012, 18(1): 23-32.
17. Farrer, N.J., Woods, J.A., Salassa, L. et al. A potent trans-diimine platinum anticancer complex photoactivated by visible light Angew Chem Int Ed Engl 2010, 49(47): 8905-8.
18. Wang And, X., Guo, Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem 2007, 7(1): 19-34. (Pubitemid 46062403)
19. Horn, L., Castellanos, E.L., Johnson, D.H. Update on new drugs in small cell lung cancer. Expert Opin Investig Drugs 2011, 20(4): 441-5.
20. William, W.N. Jr., Glisson, B.S. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011, 8(10): 611-9.
21. Tang, C.H., Parham, C., Shocron, E., McMahon, G., Patel, N. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol 2011, 67(6): 1389-400.
22. Fojo, T., Farrell, N., Ortuzar, W., Tanimura, H., Weinstein, J., Myers, T.G. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit Rev Oncol Hematol 2005, 53(1): 25-34. (Pubitemid 39656108)
23. Aris, S.M., Farrell, N.P. Towards antitumor active trans-platinum compounds. Eur J Inorg Chem 2009, 2009(10): 1293-302.
24. Murphy, R.F., Komlodi-Pasztor, E., Robey, R., Balis, F.M., Farrell, N.P., Fojo, T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum resistant cells compared to cisplatin and oxaliplatin. Cell Cycle 2012, 11(5): 963-73.
25. Farrell, N., Qu, Y., Hacker, M.P. Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem 1990, 33(8): 2179-84. (Pubitemid 20236663)
26. Farrell, N. Polynuclear platinum drugs. Met Ions Biol Syst 2004, 42: 251-96.
27. Mangrum, J.B., Farrell, N.P. Excursions in polynuclear platinum DNA binding. Chem Commun (Camb) 2010, 46(36): 6640-50.
28. Manzotti, C., Pratesi, G., Menta, E. et al. BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 2000, 6(7): 2626-34. (Pubitemid 30482097)
29. Pratesi, G., Perego, P., Polizzi, D. et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999, 80(12): 1912-9. (Pubitemid 29391274)
30. O'Connor, P.M., Jackman, J., Bae, I. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997, 57(19): 4285-300. (Pubitemid 27413438)
31. Calvert, P.H. et al. A phase I study of a novel trinuclear platinum analogue, BBR3464, in patients with advanced solid tumors. Clin Cancer Res [AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 16-19, Washington, D.C.) 1999] 1999, 5(11, Suppl.): Abst 3796.
32. Gourley, C., Cassidy, J., Edwards, C. et al. A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol 2004, 53(2): 95-101. (Pubitemid 38186986)
33. th Eur Cancer Conf (ECCO) (Oct 21-25, Lisbon) 2001] 2001, 37(Suppl. 6): Abst 965.
34. Hensing, T.A., Hanna, N.H., Gillenwater, H.H., Gabriella Camboni, M., Allievi, C., Socinski, M.A. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs 2006, 17(6): 697-704. (Pubitemid 44265869)
35. Jodrell, D.I., Evans, T.R., Steward, W. et al. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastrooesophageal adenocarcinoma. Eur J Cancer 2004, 40(12): 1872-7. (Pubitemid 39036762)
36. Vacchina, V., Torti, L., Allievi, C. et al. Sensitive species-specific monitoring of a new triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by cation-exchange HPLC-ICP-MS. J Anal At Spectrom 2003, 18(8): 884-90.
37. Oehlsen, M.E., Qu, Y., Farrell, N. Reaction of polynuclear platinum antitumor compounds with reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum coherence, and 195Pt) NMR spectroscopy. Inorg Chem 2003, 42(18): 5498-506.
38. Hoeschele, J.D., Qu, Y., Farrell, N. Tri(platinum) complexes. US 5380897.
39. Billecke, C. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro-Oncology 2006, 8(3): 215-26. (Pubitemid 46542646)
40. Manzotti, C. BBR3610. A dinuclear platinum-polyamine clinical candidate. 6th World Congr Adv Oncol, Crete, 2001.
41. Gatti, L., Perego, P., Leone, R. et al. Novel bis-platinum complexes endowed with an improved pharmacological profile. Mol Pharm 2010, 7(1):207-16.
42. Williams, J.W., Qu, Y., Bulluss, G.H., Alvorado, E., Farrell, N.P. Dinuclear platinum complexes with biological relevance based on the 1,2-diaminocyclohexane carrier ligand. Inorg Chem 2007, 46(15): 5820-2.
43. Zerzankova, L., Suchankova, T., Vrana, O., Farrell, N.P., Brabec, V., Kasparkova, J. Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles. Biochem Pharmacol 2010, 79(2): 112-21.
44. Komeda, S. Drug discovery research on in vivo antitumor-active azolato-bridged dinuclear Pt(II) complexes. Yakugaku Zasshi 2012, 132(3): 253-9.
45. Komeda, S., Moulaei, T., Woods, K.K., Chikkuma, M., Farrell, N.P., Williams, L.D. A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. J Am Chem Soc 2006, 128(50): 16092-103. (Pubitemid 44936602)
46. 4+ (BBR 3464) with its noncovalent congeners. Mol Pharmacol 2005, 69(2): 666-72.
47. Benedetti, B.T., Peterson, E.J., Kabolizadeh, P., Martinez, A., Kipping, R., Farrell, N.P. Effects of noncovalent platinum drug-protein interactions on drug efficacy: Use of fluorescent conjugates as probes for drug metabolism. Mol Pharm 2011, 8(3): 940-8.
48. Ma, Z., Choudhury, J.R., Wright, M.W., Day, C.S., Saluta, G., Kucera, G.L., Bierbach, U. A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. J Med Chem 2008, 51(23): 7574-80.
49. Park, G.Y., Wilson, J.J., Song, Y., Lippard, S.J. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci USA 2012, 109(30): 11987-92.
50. Hall, M.D., Okabe, M., Shen, D.W., Liang, X.J., Gottesman, M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008, 48: 495-535. (Pubitemid 351738162)
51. Burger, H., Loos, W.J., Eechoute, K., Verweij, J., Mathijssen, R.H., Wiemer, E.A. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011, 14(1): 22-34.
52. Silva, H., Frezard, F., Peterson, E.J., Kabolizadeh, P., Ryan, J.J., Farrell, N.P. Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds. Differential cellular accumulation mechanisms for platinum. Mol Pharm 2012, 9(6): 1795-802.
53. Wang, D., Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4(4): 307-320. (Pubitemid 41130944)
54. Plummer, R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010, 16(18): 4527-31.
55. Drew, Y., Calvert, H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann NY Acad Sci 2008, 1138: 136-45.
56. Sessa, C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 2011, 22(Suppl. 8): viii72-6.
57. Postel-Vinay, S., Vanchecke, E., Olaussen, K.A., Lord, C.J., Ahworth, A., Soria, J.C. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012, 9(3): 144-55.
58. Olszewski, U., Hamilton, G. A better platinum-based anticancer drug yet to come? Anti-Cancer Agents Med Chem 2010, 10(4): 293-301.
59. Jandial, D.D., Farschi-Heydari, S., Larson, C.A., Elliott, G.I., Wrasidio, W.J., Howell, S.B. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009, 15(2): 553-60.
60. Tanihara, Y., Masuda, S., Katsura, T., Inui, K. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 2009, 78(9): 1263-71.
61. Heim, M., Scharifi, M., Zisowsky, J., Jaehde, U., Voliotis, D., Seeber, S. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005, 16(2): 129-36. (Pubitemid 40250607)